STING1 and lipodystrophy: Similarly, the clinical trials NCT01724580 and NCT02974595 proved efficacy of baricitinib in a small group of patients affected by CANDLE (chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures) and SAVI (stimulator of IFN-genes associated vasculopaty with onset in infancy) (201, 202).